Financials data is unavailable for this security.
View more
Year on year BioLargo Inc grew revenues 107.85% from 5.88m to 12.23m while net income improved from a loss of 4.47m to a smaller loss of 3.50m.
Gross margin | 47.01% |
---|---|
Net profit margin | -24.28% |
Operating margin | -24.38% |
Return on assets | -48.80% |
---|---|
Return on equity | -41.59% |
Return on investment | -51.74% |
More ▼
Cash flow in USDView more
In 2023, BioLargo Inc increased its cash reserves by 91.19%, or 1.69m. Cash Flow from Financing totalled 4.66m or 38.09% of revenues. In addition the company used 2.37m for operations while cash used for investing totalled 478.00k.
Cash flow per share | -0.0135 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.0201 |
---|---|
Tangible book value per share | 0.0201 |
More ▼
Balance sheet in USDView more
Current ratio | 2.36 |
---|---|
Quick ratio | 2.30 |
Total debt/total equity | 0.0806 |
---|---|
Total debt/total capital | 0.0759 |
More ▼